Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-Week results of the GO-RAISE study

Annals of the Rheumatic Diseases

Volumn 71, Issue 5, 2012, Pages 661-667

  Braun, Jürgen ^a   Deodhar, Atul ^b   Inman, Robert D ^c   Van Der Heijde, Désirée ^d   Mack, Michael ^e   Xu, Stephen ^e   Hsu, Benjamin ^e  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GOLIMUMAB; PLACEBO;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; APPENDIX DISEASE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BILIRUBIN BLOOD LEVEL; BURSITIS; CELLULITIS; COCCIDIOIDOMYCOSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIOSIS; FEMALE; HUMAN; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; LUNG TUBERCULOSIS; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; PELVIC INFLAMMATORY DISEASE; PERIANAL ABSCESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; TONSILLITIS; UPPER RESPIRATORY TRACT INFECTION; UROSEPSIS;

ANTIBODIES, MONOCLONAL; BACK PAIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; HEALTH STATUS; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; JOINTS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 84859509505     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.154799     Document Type: Article

References (14)

1. Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.
2. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8. (Pubitemid 14134775)
3. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-75. (Pubitemid 351563997)
4. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
5. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
6. Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8. (Pubitemid 24285485)
7. van der Heijde D, Landewé R, Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 2008;67:489-93. (Pubitemid 351498429)
8. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
9. Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47-53.
10. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
11. Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075-86. (Pubitemid 43672920)
12. Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-34. (Pubitemid 40193618)
13. Dijkmans B, Emery P, Hakala M, et al. Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 2009;36:1256-64.
14. van der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009;68:922-9.